Lawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / April 10, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending on behalf of certain purchasers of NASDAQ: KERX shares against Keryx Biopharmaceuticals over alleged Violations of Securities Laws.

Investors who purchased shares of Keryx Biopharmaceuticals (KERX) prior to February 25, 2016 and continue to hold any NASDAQ: KERX shares have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

On August, 1, 2016 Keryx Biopharmaceuticals announced an interruption in the supply of Auryxia® (ferric citrate) tablets due to a production-related issue converting active pharmaceutical ingredient to finished drug product. Keryx Biopharmaceuticals said it expects to make Auryxia available to patients when supply is back to adequate levels. Additionally, Keryx Biopharmaceuticals has withdrawn its 2016 financial guidance.

On August 2, 2016, a lawsuit was filed against Keryx Biopharmaceuticals over alleged securities laws violations. The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product, that the issue was resulting in decreased production yields of finished drug product, that, as a result, the Company would, and did exhaust its reserve of finished drug product, and that, as a result of the foregoing, Defendants’ statements about Keryx Biopharmaceuticals’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Those who purchased Keryx Biopharmaceuticals (KERX) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

Source: finance.yahoo.com finance.yahoo.com

Be the first to comment on "Lawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders Foundation"

Leave a comment

Your email address will not be published.


*